

Effective Date: 10/01/2021
Reviewed: 07/2021
Scope: Medicaid

ORAL CALCITONIN GENE-RELATED PEPTIDE (CGRP) RECEPTOR ANTAGONISTS

NURTEC ODT (rimegepant) UBRELVY (ubrogepant)

POLICY

I. CRITERIA FOR APPROVAL

A. Acute Treatment of Migraine

An authorization may be granted for acute treatment of migraine when all of the following criteria are met:

- A. The requested drug is Nurtec ODT or Ubrovelvy
- B. Patient is 18 years of age or older
- C. Medication is prescribed by, or in consultation with a neurologist or headache specialist
- D. Patient has experienced an inadequate treatment response or intolerance to at least two preferred triptan 5-HT₁ receptor agonists (e.g., sumatriptan, rizatriptan, naratriptan) or has a contraindication that would prohibit a trial of a triptan 5-HT₁ receptor agonist
- E. For patients with a diagnosis of chronic migraines (experiencing at least 15 headache days per month), documentation is provided that the patient is using a preventive migraine medication concurrently
- F. Patient is not using medication in combination with another oral CGRP antagonist
- G. The request is within the quantity limit of 8 tablets for Nurtec ODT or 10 tablets for Ubrovelvy
 - i. If the request is exceeding the quantity limit, refer to section III for quantity limit exception criteria

B. Preventative Treatment of Episodic Migraine

An authorization may be granted for the preventative treatment of episodic migraine when all of the following criteria are met:

- A. The requested drug is Nurtec ODT
- B. Patient is 18 years of age or older
- C. Medication is prescribed by, or in consultation with a neurologist or headache specialist
- D. Patient experiences at least 4 but not more than 14 headache days per month, with disability on some days
- E. Patient has been fully equipped with abortive migraine therapy, if appropriate, and has had inadequate relief
- F. Patient has documented trial and failure of a 3-month trial of any 2 prophylactic medications from the following therapeutic classes:
 - i. Antidepressants (e.g., amitriptyline, venlafaxine)
 - ii. Beta blockers (e.g., propranolol, metoprolol, timolol, atenolol)
 - iii. Anti-epileptics (e.g., topiramate, valproate)
- H. Patient is not using medication in combination with another oral CGRP antagonist, an injectable CGRP antagonist (e.g., Ajoovy, Emgality, Vyepti), or a botulinum toxin (e.g., onabotulinumtoxinA, abobotulinumtoxinA, incobotulinumtoxinA, rimabotulinumtoxinB)
- I. Patient meets either the following criteria:
 - i. The request is within the quantity limit of 8 tablets for Nurtec ODT for periodic prevention

Effective Date: 10/01/2021
Reviewed: 07/2021
Scope: Medicaid

- ii. Patient has a documented trial and failure of a preferred injectable CGRP antagonist (Ajovy or Emgality) for migraine prevention

II. CONTINUATION OF THERAPY

A. Acute Treatment of Migraine

An authorization may be granted for acute treatment of migraine when all of the following criteria are met:

- A. Patient is not using medication in combination with another oral CGRP antagonist
- B. Patient has experienced a positive clinical response to therapy as demonstrated by a reduction in headache pain, duration and/or severity from baseline.
- C. The request is within the quantity limit of 8 tablets for Nurtec ODT or 10 tablets for Ubrelyv
 - i. If the request is exceeding the quantity limit, refer to section III for quantity limit exception criteria

B. Preventative Treatment of Episodic Migraine

An authorization may be granted for the preventative treatment of episodic migraine when all of the following criteria are met:

- A. Patient is not using medication in combination with another oral CGRP antagonist, an injectable CGRP antagonist (e.g., Ajovy, Emgality, Vyepti), or a botulinum toxin (e.g., onabotulinumtoxinA, abobotulinumtoxinA, incobotulinumtoxinA, rimabotulinumtoxinB)
- B. Patient has experienced a positive clinical response to therapy as demonstrated by a reduction in headache frequency, duration and/or severity from baseline
- C. The request is within the quantity limit of 8 tablets for Nurtec ODT
 - i. If the request is exceeding the quantity limit, refer to section III for quantity limit exception criteria

III. QUANTITY LIMIT

- Nurtec ODT: 8 tablets per month (30 days), post-limit of up to 18 tablets per 30 days
 - A quantity limit exception of more than 8 tablets per month up to a max of 18 tablets per month for preventative use would require a documented trial and failure of a preferred injectable CGRP antagonist (Ajovy or Emgality), or documentation is provided that the patient is using a preventative migraine medication concurrently when Nurtec ODT is being used for acute treatment
- Ubrelyv: 10 tablets per month (30 days), post-limit of up to 16 tablets per 30 days
 - A quantity limit exception of more than 10 tablets per month up to a max of 16 tablets per 30 days would require that documentation is provided that the patient is using a preventative migraine medication concurrently, and documentation that the optimized dosage strength of Ubrelyv is being utilized based on tolerability

IV. COVERAGE DURATION

- Initial: 6 months
- Continuation: 12 months